• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Hyperfine Inc. (Amendment)

    12/6/22 6:58:36 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $HYPR alert in real time by email
    SC 13D/A 1 d423465dsc13da.htm SC 13D/A (AMENDMENT NO.1) SC 13D/A (Amendment No.1)

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No.    1)*

     

     

    Hyperfine, Inc.

    (Name of Issuer)

    Class A common stock, par value $0.0001 per share

    Class B common stock, par value $0.0001 per share

    (Title of Class of Securities)

    Class A common stock: 44916K106

    Class B common stock: Not Applicable

    (CUSIP Number)

    Jonathan M. Rothberg, Ph.D.

    c/o Hyperfine, Inc.

    351 New Whitfield Street

    Guilford, Connecticut 06437

    (866) 796-6767

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    Copies to:

    Michael L. Fantozzi, Esq.

    John P. Condon, Esq.

    Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

    One Financial Center

    Boston, Massachusetts 02111

    November 30, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


       SCHEDULE 13D   
    CUSIP NO. 74765K105    13D    Page 2 of 9

     

      1    

      NAMES OF REPORTING PERSON

     

      Jonathan M. Rothberg, Ph.D.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      PF1

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      2,440,886 shares of Class A common stock and 15,055,288 shares of Class B common stock1

         8   

      SHARED VOTING POWER

     

      535,802 shares of Class A common stock2

         9   

      SOLE DISPOSITIVE POWER

     

      2,440,886 shares of Class A common stock and 15,055,288 shares of Class B common stock1

       10   

      SHARED DISPOSITIVE POWER

     

      535,802 shares of Class A common stock2

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,976,688 shares of Class A common stock and 15,055,288 shares of Class B common stock

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      5.3% of the Class A common stock and 100% of the Class B common stock3

    14  

      TYPE OF REPORTING PERSON

     

      IN

     

    1 

    Consists of (i) 104,074 shares of Class A common stock of Hyperfine, Inc. (f/k/a HealthCor Catalio Acquisition Corp.) (the “Issuer”) held by Jonathan M. Rothberg, Ph.D. and 762,047 shares of Class A common stock of the Issuer held by Jonathan M. Rothberg 2003 Revocable Trust, (ii) restricted stock units (“RSUs”) for 6,528 shares of Class A common stock of the Issuer, which vest within 60 days of November 30, 2022, held by Dr. Jonathan Rothberg, (iii) a stock option to purchase 982,500 shares of Class A common stock of the Issuer held by Dr. Jonathan Rothberg, (vi) 585,737 shares of Class A common stock of the Issuer held by 2012 JMR Trust Common, LLC, (v) 6,867,790 shares of Class B common stock of the Issuer held by 4C Holdings I, LLC, (vi) 7,368,748 shares of Class B common stock of the Issuer distributed from 4C Holdings I, LLC and held by entities owned by trusts created for the benefit of Dr. Jonathan Rothberg’s children, and (vii) 818,750 shares of Class B common stock of the Issuer held by 4C Holdings V, LLC.

    2 

    Consists of (i) 440,295 shares of Class A common stock of the Issuer held by 23rd Century Capital LLC, and (ii) 95,507 shares of Class A common stock of the Issuer held by Dr. Jonathan Rothberg’s spouse, Bonnie E. Gould Rothberg, M.D.

    3 

    Calculated based on 55,520,444 shares of Class A common stock of the Issuer and 15,055,288 shares of Class B common stock of the Issuer outstanding as of November 1, 2022, as reported in the Issuer’s Form 10-Q as filed with the Securities and Exchange Commission on November 10, 2022.


       SCHEDULE 13D   
    CUSIP NO. 74765K105    13D    Page 3 of 9

     

      1    

      NAMES OF REPORTING PERSON

     

      23rd Century Capital LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      PF

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

         8   

      SHARED VOTING POWER

     

      440,295 shares of Class A common stock

         9   

      SOLE DISPOSITIVE POWER

     

       10   

      SHARED DISPOSITIVE POWER

     

      440,295 shares of Class A common stock

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      440,295 shares of Class A common stock

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      Less than 1% of the Class A common stock4

    14  

      TYPE OF REPORTING PERSON

     

      OO

      

     

    4 

    Calculated based on 55,520,444 shares of Class A common stock of the Issuer outstanding as of November 1, 2022, as reported in the Issuer’s Form 10-Q as filed with the Securities and Exchange Commission on November 10, 2022.


       SCHEDULE 13D   
    CUSIP NO. 74765K105    13D    Page 4 of 9

     

      1    

      NAMES OF REPORTING PERSON

     

      2012 JMR Trust Common, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      PF

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

         8   

      SHARED VOTING POWER

     

      585,737 shares of Class A common stock

         9   

      SOLE DISPOSITIVE POWER

     

       10   

      SHARED DISPOSITIVE POWER

     

      585,737 shares of Class A common stock

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      585,737 shares of Class A common stock

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      1.1% of the Class A common stock5

    14  

      TYPE OF REPORTING PERSON

     

      OO

      

     

    5 

    Calculated based on 55,520,444 shares of Class A common stock of the Issuer outstanding as of November 1, 2022, as reported in the Issuer’s Form 10-Q as filed with the Securities and Exchange Commission on November 10, 2022.


       SCHEDULE 13D   
    CUSIP NO. 74765K105    13D    Page 5 of 9

     

      1    

      NAMES OF REPORTING PERSON

     

      4C Holdings I, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      PF

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

         7     

      SOLE VOTING POWER

     

         8   

      SHARED VOTING POWER

     

      6,867,790 shares of Class B common stock

         9   

      SOLE DISPOSITIVE POWER

     

       10   

      SHARED DISPOSITIVE POWER

     

      6,867,790 shares of Class B common stock

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      6,867,790 shares of Class B common stock

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      45.6% of the Class B common stock6

    14  

      TYPE OF REPORTING PERSON

     

      OO

     

    6 

    Calculated based on 15,055,288 shares of Class B common stock of the Issuer outstanding as of November 1, 2022, as reported in the Issuer’s Form 10-Q as filed with the Securities and Exchange Commission on November 10, 2022.


       SCHEDULE 13D   
    CUSIP NO. 74765K105    13D    Page 6 of 9

     

      1    

      NAMES OF REPORTING PERSON

     

      4C Holdings V, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      PF

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

         7     

      SOLE VOTING POWER

     

         8   

      SHARED VOTING POWER

     

      818,750 shares of Class B common stock

         9   

      SOLE DISPOSITIVE POWER

     

       10   

      SHARED DISPOSITIVE POWER

     

      818,750 shares of Class B common stock

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      818,750 shares of Class B common stock

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      5.4% of the Class B common stock7

    14  

      TYPE OF REPORTING PERSON

     

      OO

     

    7 

    Calculated based on 15,055,288 shares of Class B common stock of the Issuer outstanding as of November 1, 2022, as reported in the Issuer’s Form 10-Q as filed with the Securities and Exchange Commission on November 10, 2022.


       SCHEDULE 13D   
    CUSIP NO. 74765K105    13D    Page 7 of 9

     

    Explanatory Note

    This Amendment No. 1 to Schedule 13D (“Amendment No. 1”) amends and supplements the Schedule 13D filed on December 30, 2021 (the “Schedule 13D”) relating to the Class A common stock, par value $0.0001 per share, and Class B common stock, par value $0.0001 per share, of Hyperfine, Inc. (f/k/a HealthCor Catalio Acquisition Corp.), a Delaware corporation (the “Issuer”). Information reported in the Schedule 13D remains in effect except to the extent that it is amended, restated or superseded by information contained in this Amendment No. 1. Capitalized terms used but not defined herein have the meanings ascribed to them in the Schedule 13D.

    Item 1. Security and Issuer.

    There are no changes to the Item 1 information previously filed.

    Item 2. Identity and Background.

    Item 2 sections (c) and (f) of the Schedule 13D is hereby amended and restated in its entirety below:

    (c) Dr. Jonathan Rothberg is the founder of Legacy Hyperfine (defined below) and a member of the Board of Directors of the Issuer. He is a member of 23rd Century Capital LLC, a trustee of the 2003 Jonathan M. Rothberg Revocable Trust, and is the sole manager of 2012 JMR Trust Common, LLC, 4C Holdings I, LLC, 4C Holdings V, LLC, and the limited liability company distributees of 4C Holdings I, LLC. Dr. Jonathan Rothberg is the founder of the 4Catalyzer medical technology incubator and the founder and Chairman of its companies.

    (f) Dr. Jonathan Rothberg is a citizen of the United States of America. Each of 23rd Century Capital LLC, 2012 JMR Trust Common, LLC, 4C Holdings I, LLC, 4C Holdings V, LLC, and the limited liability company distributees of 4C Holdings I, LLC is a limited liability company organized under the laws of Delaware.

    Item 3. Source and Amount of Funds or Other Consideration.

    Item 3 of the Schedule 13D is hereby amended and supplemented by adding the following:

    As set forth in Annex A, between June 14, 2022 and November 30, 2022, Dr. Jonathan Rothberg purchased an aggregate of 762,047 shares of Class A common stock of the Issuer in open market transactions.

    Item 4. Purpose of Transaction.

    Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following:

    The information set forth in Item 3 above is incorporated into this Item 4 by reference.

    Item 5. Interest in Securities of the Issuer.

    Item 5 of the Schedule 13D is hereby amended and supplemented by adding the following:

    The information set forth in Item 3 above is incorporated into this Item 5 by reference.

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

    There are no changes to the Item 6 information previously filed.

    Item 7. Material to be Filed as Exhibits.

    There are no changes to the Item 7 previously filed.


       SCHEDULE 13D   
    CUSIP NO. 74765K105    13D    Page 8 of 9

     

    SIGNATURE

    After reasonable inquiry and to the best of the undersigned’s knowledge and belief, the undersigned hereby certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: December 6, 2022    

    /s/ Jonathan M. Rothberg

        Jonathan M. Rothberg, Ph.D.
       

    23rd Century Capital LLC

     

        By:  

    /s/ Jonathan M. Rothberg

        Name:   Jonathan M. Rothberg, Ph.D.
        Title:   Member
       

    2012 JMR Trust Common, LLC

     

        By:  

    /s/ Jonathan M. Rothberg

        Name:   Jonathan M. Rothberg, Ph.D.
        Title:   Manager
       

    4C Holdings I, LLC

     

        By:  

    /s/ Jonathan M. Rothberg

        Name:   Jonathan M. Rothberg, Ph.D.
        Title:   Manager
       

    4C Holdings V, LLC

     

        By:  

    /s/ Jonathan M. Rothberg

        Name:   Jonathan M. Rothberg, Ph.D.
        Title:   Manager


    Annex A

    Trading History

    The following transactions were effected by Dr. Jonathan Rothberg in Class A common stock of the Issuer between June 14, 2022 and November 30, 2022:

     

    Trade Date

      Amount
    Purchased
        Weighted
    Average Price
    Per Share
     
    06/14/2022     52,848     $ 2.26  
    08/12/2022     303,137     $ 1.457  
    08/16/2022     64,213     $ 1.482  
    11/14/2022     34,488     $ 0.89  
    11/15/2022     31,139     $ 0.92  
    11/29/2022     47,007     $ 0.72  
    11/30/2022     229,215     $ 0.82  
    Get the next $HYPR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HYPR

    DatePrice TargetRatingAnalyst
    8/11/2022$8.00 → $2.40Overweight → Equal Weight
    Wells Fargo
    5/31/2022$7.00Outperform
    Evercore ISI
    4/14/2022$8.00Overweight
    Wells Fargo
    More analyst ratings

    $HYPR
    SEC Filings

    View All

    SEC Form 10-Q filed by Hyperfine Inc.

    10-Q - Hyperfine, Inc. (0001833769) (Filer)

    8/13/25 4:15:45 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hyperfine Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Hyperfine, Inc. (0001833769) (Filer)

    8/13/25 4:10:27 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hyperfine Inc. filed SEC Form 8-K: Other Events

    8-K - Hyperfine, Inc. (0001833769) (Filer)

    8/6/25 4:01:27 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HYPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hyperfine, Inc. Reports Second Quarter 2025 Financial Results

    GUILFORD, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced second quarter 2025 financial results and provided a business update. "In the second quarter, we executed across our key growth drivers. We received FDA clearances for our latest software, Optive AITM, and for the next generation Swoop® system powered by Optive AITM software, which represent a key inflection point in our technology. We also completed our pilot neurology office program. We believe these criti

    8/13/25 4:05:00 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hyperfine Achieves Clinical Milestone Ahead of Plan With 100th Patient Enrolled in Neurology Office Study Using the Next-Generation Swoop® System

    NEURO PMR study evaluates the clinical utility and patient experience of AI-powered portable MRI in an outpatient setting Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system— today announced the successful enrollment of 100 patients in its NEURO PMR (Neurological Evaluation in the Office with Portable MRI) study just 16 weeks after the study initiation, announced on April 15, 2025. This milestone reflects strong clinician enthusiasm for accessible, point-of-care brain imaging and supports Hyperfine's market expansion into outpatient neurology o

    8/4/25 8:15:00 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hyperfine Announces First Patients Enrolled in PRIME Study Aimed at Accelerating Adoption of AI-Powered Portable MRI in Emergency Departments

    The real-world study will assess the clinical and operational impact of portable MRI across diverse patient types in ED settings. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance imaging (MRI) system for the brain—the Swoop® system—today announced the enrollment of the first patients in the PRIME (Portable Rapid Imaging for Medical Emergencies) study. This study aims to evaluate the potential of AI-powered portable MRI technology to transform triage in the emergency department (ED) setting. The PRIME study at Yale School of Medicine builds on the ACTION PMR study

    7/31/25 8:15:00 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HYPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Teisseyre Thomas sold $1,531 worth of shares (1,151 units at $1.33), decreasing direct ownership by 0.30% to 381,062 units (SEC Form 4)

    4 - Hyperfine, Inc. (0001833769) (Issuer)

    8/18/25 4:10:40 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Wolterman Dan

    4 - Hyperfine, Inc. (0001833769) (Issuer)

    6/6/25 4:01:04 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CFO and CAO Hale Brett was granted 300,000 shares (SEC Form 4)

    4 - Hyperfine, Inc. (0001833769) (Issuer)

    5/20/25 5:26:31 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HYPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Hyperfine downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Hyperfine from Overweight to Equal Weight and set a new price target of $2.40 from $8.00 previously

    8/11/22 6:32:27 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Evercore ISI initiated coverage on Hyperfine with a new price target

    Evercore ISI initiated coverage of Hyperfine with a rating of Outperform and set a new price target of $7.00

    5/31/22 7:16:51 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Wells Fargo initiated coverage on Hyperfine with a new price target

    Wells Fargo initiated coverage of Hyperfine with a rating of Overweight and set a new price target of $8.00

    4/14/22 7:32:25 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HYPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Hyperfine Inc.

    SC 13G - Hyperfine, Inc. (0001833769) (Subject)

    2/13/24 5:06:19 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Hyperfine Inc. (Amendment)

    SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)

    2/14/23 4:07:09 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Hyperfine Inc. (Amendment)

    SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)

    12/20/22 4:22:37 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HYPR
    Leadership Updates

    Live Leadership Updates

    View All

    QuidelOrtho Announces Appointment of Two Independent Directors to its Board

    Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

    12/10/24 7:00:00 AM ET
    $CTLT
    $HYPR
    $NVST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    Hyperfine Announces Strategic Leadership Additions to Drive Growth in Key Business Verticals

    Two new executive roles position Hyperfine to drive the adoption of the Swoop® system in hospital settings and expand into the office setting, laying the foundation for significant growth in 2025 and beyond. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the appointment of Chi Nguyen as Vice President of Office Strategy and Partnerships and Rafael Donnay as Vice President of Hospital Strategy and Health Economics to provide leadership in key growth areas. These strategic leadership appointments bolster t

    12/3/24 9:00:00 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hyperfine, Inc. Continues Global Market Expansion by Entering Into a Distribution Partnership with Radiosurgery Global, Ltd. to Bring the Swoop® System to India

    Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced it has entered into a distribution agreement with Radiosurgery Global, Ltd. to develop the market in India. The distribution agreement also includes the countries of Malaysia, Indonesia, and Singapore through future expansion, offering Hyperfine, Inc. a significantly increased presence in Asia. The clinical value of the Swoop®

    5/28/24 9:00:00 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HYPR
    Financials

    Live finance-specific insights

    View All

    Hyperfine, Inc. Reports Second Quarter 2025 Financial Results

    GUILFORD, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced second quarter 2025 financial results and provided a business update. "In the second quarter, we executed across our key growth drivers. We received FDA clearances for our latest software, Optive AITM, and for the next generation Swoop® system powered by Optive AITM software, which represent a key inflection point in our technology. We also completed our pilot neurology office program. We believe these criti

    8/13/25 4:05:00 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hyperfine, Inc. to Announce Second Quarter 2025 Financial Results on August 13, 2025

    Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that it will report financial results for the second quarter 2025 on Wednesday, August 13, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. About the Swoo

    7/30/25 4:05:00 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hyperfine, Inc. to Announce First Quarter 2025 Financial Results on May 13, 2025

    Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. About the Swo

    4/29/25 4:28:00 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care